Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.452 +0.052 (+3.74%)

Delayed Quote Updated: 9:47 AM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,266
Open	1.450
Bid (Size)	1.440 (4,800)
Ask (Size)	1.490 (300)
Prev. Close	1.400
Today's Range	1.428 - 1.473
52wk Range	1.250 - 5.480
Shares Outstanding	45,484,310
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders ↗

October 01, 2026

Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through...

Via MarketBeat

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

September 29, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-69.7%	-69.7%
1 Month	-56.0%	-56.0%
3 Month	-56.0%	-56.0%
6 Month	-57.4%	-57.4%
1 Year	-55.9%	-55.9%

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

September 22, 2026

From Pomerantz LLP

Via GlobeNewswire

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

September 19, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

September 17, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

September 17, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

September 16, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

September 14, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

September 11, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Announces Participation in Upcoming Investor Conferences

September 01, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Reports Financial Results for the Second Quarter 2026

August 06, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Report Second Quarter Financial Results on August 6, 2026

July 30, 2026

From Cellectis Inc.

Via GlobeNewswire

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026

From ProLynx Inc.

Via GlobeNewswire

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

June 25, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

June 11, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

June 09, 2026

From Cellectis Inc.

Via GlobeNewswire

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Via The Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Via The Motley Fool

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

May 20, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

May 12, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Reports Financial Results for the First Quarter 2026

May 11, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Report First Quarter Financial Results on May 11, 2026

May 04, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

April 27, 2026

From Cellectis Inc.

Via GlobeNewswire

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

April 13, 2026

From Cellectis Inc.

Via GlobeNewswire

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

Frequently Asked Questions

Is Cellectis S.A. - American Depositary Shares publicly traded?

Yes, Cellectis S.A. - American Depositary Shares is publicly traded.

What exchange does Cellectis S.A. - American Depositary Shares trade on?

Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Cellectis S.A. - American Depositary Shares?

The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market

What is the current price of Cellectis S.A. - American Depositary Shares?

The current price of Cellectis S.A. - American Depositary Shares is 1.452

When was Cellectis S.A. - American Depositary Shares last traded?

The last trade of Cellectis S.A. - American Depositary Shares was at 10/02/26 09:47 AM ET

What is the market capitalization of Cellectis S.A. - American Depositary Shares?

The market capitalization of Cellectis S.A. - American Depositary Shares is 66.06M

How many shares of Cellectis S.A. - American Depositary Shares are outstanding?

Cellectis S.A. - American Depositary Shares has 66M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.